Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report sent to investors on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, Dawson James initiated coverage on shares of Tonix Pharmaceuticals in a report on Wednesday, February 28th. They issued a buy rating and a $3.00 target price on the stock.

Tonix Pharmaceuticals Stock Performance

Shares of NASDAQ:TNXP opened at $0.18 on Friday. The company has a market cap of $15.17 million, a P/E ratio of -0.02 and a beta of 2.21. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $3.31. The business’s 50-day simple moving average is $0.27 and its 200 day simple moving average is $0.37. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.81 and a current ratio of 2.53.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Monday, April 1st. The company reported ($0.86) earnings per share (EPS) for the quarter. The firm had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.95 million. On average, sell-side analysts forecast that Tonix Pharmaceuticals will post -3.71 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Sabby Management LLC purchased a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,247,465 shares of the company’s stock, valued at approximately $680,000. Tonix Pharmaceuticals makes up 0.5% of Sabby Management LLC’s holdings, making the stock its 6th biggest holding. Sabby Management LLC owned about 7.02% of Tonix Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.